Inventaire - teman dan komunitas anda adalah perpustakaan terbaik - Inventaire

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase

pengarang

Simona Soverini

Giuseppe Saglio

Andreas Hochhaus

Jorge Eduardo Cortes

Giovanni Martinelli

Lan Beppu

Enrico Gottardi

Susan Branford

Jerald P Radich

Yaping Shou

Ariful Haque Abir

Philipp Erben

diterbitkan dalam: Journal of Clinical Oncology

tanggal publikasi: 2009-08-03

bahasa: Inggris

subyek utama: chronic myeloid leukemia, leukemia

Cites articles 27

Date

Judul

Pengarang

2008-12-01

Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression
2008-07-04

ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia.

Andreas Hochhaus
2007-12-01

Part II: management of resistance to imatinib in chronic myeloid leukaemia
2007-11-29

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

Elisabetta Abruzzese, Oliver Ottmann, Giuseppe Saglio, Andreas Hochhaus, Richard A. Larson, Hagop Kantarjian, Jorge Eduardo Cortes, Giovanni Martinelli, Michele Baccarani, Francis Giles, Norbert Gattermann, Kazimierz Kuliczkowski, Jane F Apperley, Jerald P Radich, Philipp le Coutre, Francois-Xavier Mahon, Yaping Shou
2007-08-22

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

Francesca Palandri, Andreas Hochhaus, Hagop Kantarjian, Giuliana Alimena, Francis Giles, Norbert Gattermann, Mark R Litzow
2007-09

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
2007-10-01

The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells

Carlo Gambacorti-Passerini, François Guilhot, Brian Druker, Andreas Hochhaus, Hagop Kantarjian, Jorge Eduardo Cortes, Michele Baccarani, Dietger Niederwieser, Ron L Paquette
2007-02-15

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study
2007-01-25

Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib

Michael C. Heinrich, Brian Druker, Richard D Press
2007-03-01

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain

Simona Soverini, Michela Rondoni, Francesca Palandri, Nicoletta Testoni, Giuseppe Saglio, Giulia Marzocchi, Stefania Paolini, Daniela Cilloni, Pier Paolo Piccaluga, Costanza Bosi, Panagiota Giannoulia, Giovanni Martinelli, Sabrina Colarossi, Alessandra Gnani, Fausto Castagnetti, Ilaria Iacobucci
2007-03

Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL

Michela Rondoni, Simona Soverini, Gianantonio Rosti, Fausto Castagnetti, Giovanni Martinelli, Michele Baccarani, Stefania Paolini, Alessandra Gnani, Sabrina Colarossi
2006-12-01

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Brian Druker, François Guilhot, Andreas Hochhaus, Giuseppe Saglio, Richard A. Larson, Alois Gratwohl, Norbert Gattermann, Gregor Verhoef
2006-09-14

Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia

Andreas Hochhaus
2006-06-19

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
2006-03-07

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

Suzanne Kamel-Reid, Simona Soverini, Brian Druker, Giuseppe Saglio, Andreas Hochhaus, Jorge Eduardo Cortes, Giovanni Martinelli, Michele Baccarani, Susan Branford, Jerald P Radich, Rüdiger Hehlmann
2006-12-15

Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia

Mario Tiribelli, Simona Soverini, Elisabetta Abruzzese, Giuseppe Saglio, Gianantonio Rosti, Fausto Castagnetti, Giovanni Martinelli, Michele Baccarani, Ilaria Iacobucci, Angela Poerio, Alessandra Gnani, Sabrina Colarossi, Marilina Amabile, Fabrizio Pane, Barbara Izzo, Ester Orlandi, Clementina Caracciolo, Franca Radaelli
2005-07-01

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia

Hagop Kantarjian, Srdan Verstovsek, Jorge Eduardo Cortes, Francis Giles, Taghi Manshouri, Margaret Dugan, Leila Alland, Mirna Golemovic
2005-02-01

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

Andrew L. Kung, George Q. Daley, Donna Neuberg
2005-05-24

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy.

Brian Druker, Dietger Niederwieser
2005-04-01

Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.

Andreas Hochhaus, Claudia Schoch
2005-06-20

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

Simona Soverini, Elisabetta Abruzzese, Nicoletta Testoni, Giuseppe Saglio, Gianantonio Rosti, Fausto Castagnetti, Giovanni Martinelli, Michele Baccarani, Simona Luatti, Daniela Cilloni, Angela Poerio, Elena Trabacchi, Marilina Amabile, Fabrizio Pane, Barbara Giannini, Simona Bassi, Barbara Izzo, Milena Fava
2004-08-01

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

Andreas Hochhaus
2003-02-06

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

Brian Druker, Paul La Rosée
2003-03-06

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

Jeff Szer
2002-11-01

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

Andreas Hochhaus, Brian Druker
2002-08

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
2002-05-01

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

Artikel - wd:Q37163834

Selamat datang di Inventaire

perpustakaan teman-teman dan komunitas anda

pelajari lebih lanjut

anda sedang luring